John Gordon Freund
CIK 1296771 · last filed 2026-06-08
John Gordon Freund is a corporate insider who has filed 126 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for SIBN, was dated Jun 8, 2026. Across all open-market trades the lifetime net is +$480.73B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.8M across reported positions. 20 SEC filings were submitted jointly with YASUNORI KANEKO.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.84M
12
126
$480.73B
Filer Profile
C/O SKYLINE VENTURES
PALO ALTO, CA 94301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SIBN | Director | 146,025 | $18.56 | $2.71M | -$49.95M | 21 | 2026-06-08 |
| COLL | Director | 107,081 | $22.70 | $2.43M | $1.05M | 14 | 2026-05-20 |
| STRO | Director | 0 | $16.07 | $0 | -$14.16M | 13 | 2024-06-10 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Director | 0 | — | — | -$9.95M | 15 | 2019-12-12 |
| PRTO | Director | 59,397 | $27.60 | $1.64M | $7.20M | 8 | 2019-11-12 |
| COLLEGIUM PHARMACEUTICAL, INC (ESPR) Delisted | Director | 33,325 | $3.18 | $106.0K | $0 | 7 | 2019-04-29 |
| XENOPORT INC (XNPT) Delisted | Director | 0 | — | — | $17.87M | 18 | 2016-07-06 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 1,058,920 | $8.37 | $8.86M | $2.10M | 1 | 2014-02-21 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 208,097 | $0.86 | $179.0K | $4.84M | 1 | 2012-05-31 |
| MAPP | Director | 1,984 | $28.11 | $55.8K | $3.00M | 10 | 2011-05-23 |
| HANSEN MEDICAL INC (HNSN) Delisted | Director | 200,094 | — | — | $480.77B | 3 | 2009-06-17 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 304,761 | — | — | $0 | 1 | 2007-05-31 |
Recent Filings
126 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | SIBN | Grant (A) | +10,957 | $0 | EDGAR |
| 2026-05-20 | COLL | Sell (S) | −20 | -$681 | EDGAR |
| 2026-05-18 | COLL | Notice (144) | −30 | -$1.0K | EDGAR |
| 2026-05-18 | COLL | Mixed | +13,314 | $916 | EDGAR |
| 2026-05-15 | COLL | Notice (144) | −4,127 | -$142.5K | EDGAR |
| 2025-08-12 | COLL | Sell (S) | −11,659 | -$400.6K | EDGAR |
| 2025-08-11 | SIBN | Sell (S) | −12,132 | -$194.0K | EDGAR |
| 2025-06-11 | COLL | Mixed | +8,399 | -$399 | EDGAR |
| 2025-06-09 | COLL | Notice (144) | −6,601 | -$202.1K | EDGAR |
| 2025-06-06 | SIBN | Grant (A) | +8,675 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.